Background Bismuth‐containing quadruple therapy (BQT) is a recommended alternative first‐
line therapy for Helicobacter pylori (H. pylori) infection. We aim to evaluate the efficacy and …

Background: Bismuth‐containing quadruple therapy given twice a day for 14 days has been
shown to be an excellent first‐line H. pylori eradication therapy. Aim: To compare the …

Background The aim of this study was to evaluate the efficacy, tolerability and safety of
modified bismuth-based quadruple therapy for the second-line eradication treatment of …

Background Bismuth quadruple therapy (BQT) has been proven superior to standard triple
therapy for Helicobacter pylori eradication in randomized clinical trials; however, little is …

Background Rising antibiotic resistance requires the evaluation of new and effective
therapies. Aims To test the efficacy and safety of the new bismuth‐containing quadruple …

Aim To compare the efficacy and safety between modified quadruple-and bismuth-
containing quadruple therapy as first-line eradication regimen for Helicobacter pylori …

Background/aims Helicobacter pylori eradication rates with standard triple regimens are
worsening, and alternative treatments are urgently needed in some populations. The …

Background Due to general unavailability and common side effects of tetracycline, the
clinical application of bismuth quadruple therapy (BQT) is greatly limited. Whether …

BACKGROUND: Helicobacter pylori eradication rates have tended to decrease recently,
mostly due to increasing antibiotic‐resistance. The present study aimed to compare the …

Background & Aims Due to the poor eradication rates of standard triple therapy, the addition
of bismuth salts has been proposed for first-line eradication of Helicobacter pylori. We …